B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.

The goal of this clinical trial is to develop a new cancer diagnostic and prognostic tool based on the dynamic and non-invasive detection of an exogenous volatile molecule, i.e., ethanol, from patients' samples. Patients' blood plasma will be analyzed with a mixture of volatile organic compound-based probes, each targeting a specific glycosidase. The presence of a given glycosidase in a blood sample would thus be revealed by the detection of an ethanol isotope in the gas phase. 3 groups of patients with localized cancer (breast, prostate, pancreas) will be enrolled, as well as 1 group of patient without any cancer (control group). For the patients, two 5ml plasma samples will be collected, one before and one after surgery for localized cancers. For healthy volunteers, only one 5ml plasma sample will be collected. The primary objective will be to compare the levels of glycosidases measured in the blood of patients followed for localized cancer and referred for first surgery compared to control patients without cancer.

NCT Number	NCT07236177
Lead Sponsor	Poitiers University Hospital
Conditions	Breast Cancer, Pancreatic Cancer, Pulmonary Cancer, Volatile Organic Compound, Glycosidase Activity, Probes, Tumor Markers, Biological
Enrollment	220 participants
Start Date	2026-02-03
Primary Completion	2028-02-03 (estimated)
Study Completion	2028-03-03 (estimated)
Updated on ClinicalTrials.gov	2026-02-05